13F HOLDINGS REPORT
Caligan Partners LP
Quarter ended Q1 2024 · Filed May 13, 2024 · Accession 0001727492-24-000006
Total Value
$378.3M
Positions
12
Other Managers
0
Confidential Omitted
No
Holdings (12)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | LIQUIDIA CORPORATION | LQDA | 10,360,945 | $152.8M | 40.40% |
| 2 | ALIMERA SCIENCES INC | 016259202 | 16,835,154 | $65.7M | 17.36% |
| 3 | ANIKA THERAPEUTICS INC | ANIK | 1,435,993 | $36.5M | 9.64% |
| 4 | EVOLUS INC | EOLS | 1,888,881 | $26.4M | 6.99% |
| 5 | EXELIXIS INC | EXEL | 1,100,730 | $26.1M | 6.90% |
| 6 | VERONA PHARMA PLC | 925050106 | 1,296,447 | $20.9M | 5.51% |
| 7 | ENANTA PHARMACEUTICALS INC | ENTA | 858,070 | $15.0M | 3.96% |
| 8 | AGIOS PHARMACEUTICALS INC | AGIO | 484,711 | $14.2M | 3.75% |
| 9 | Y-MABS THERAPEUTICS INC | 984241109 | 587,276 | $9.5M | 2.52% |
| 10 | OUTLOOK THERAPEUTICS INC | OTLK | 500,000 | $6.0M | 1.58% |
| 11 | BIOCRYST PHARMACEUTICALS INC | BCRX | 758,502 | $3.9M | 1.02% |
| 12 | I MAB | NBP | 756,538 | $1.4M | 0.37% |